Hostname: page-component-848d4c4894-m9kch Total loading time: 0 Render date: 2024-06-11T15:16:24.923Z Has data issue: false hasContentIssue false
  • English
  • Français

Enhancing central noradrenergic function in depression: is there still a place for a new antidepressant?

Published online by Cambridge University Press:  24 June 2014

Roger M. Pinder
Roger M. Pinder*
Affiliation:
Medical Affairs, Organon International Inc, Roseland, NJ, USA
*
Roger M. Pinder, PhD, DSc, Vice-President Medical Affairs, CNS & Thrombosis, Organon International Inc, 56, Livingston Avenue, Roseland, NJ 07068, USA. Tel: (1) 973 325 4812; Fax: (1) 973 325 4699; E-mail: r.pinder@organonusa.com
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Original Article
Information
Acta Neuropsychiatrica , Volume 16 , Issue 4 , August 2004 , pp. 185 - 189
Copyright
Copyright © 2004 Blackwell Munksgaard

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Schildkraut, JJ. Catecholamine hypothesis of affective disorders: a review of the supporting evidence. Am J Psychiatry 1965;130: 695–699. CrossRefGoogle Scholar
Coppen, A. The biochemistry of affective disorders. Br J Psychiatry 1967;113: 1237–1264.CrossRefGoogle ScholarPubMed
Pinder, RM, Brogden, RN, Speight, TM, Avery, GS. Maprotiline: a review of its pharmacological properties and therapeutic efficacy in mental depressive states. Drugs 1977;13: 321–352.CrossRefGoogle ScholarPubMed
Pinder, RM, Brogden, RN, Speight, TM, Avery, GS. Viloxazine: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs 1977;13: 401–421.CrossRefGoogle ScholarPubMed
Pinder, RM, Wieringa, JH. Third-generation antidepressants. Med Res Rev 1993;13: 259–325.CrossRefGoogle ScholarPubMed
Anderson, IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000;58: 19–36.DOI: 10.1016/S0165-0327(99)00092-0CrossRefGoogle ScholarPubMed
Nierenberg, AA. Do some antidepressants work faster than others? J Clin Psychiatry 2001;62 (Suppl. 15):22–25.Google ScholarPubMed
Smith, D, Dempster, C, Glanville, J, Freemantle, N, Anderson, I. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 2002;180: 396–404.DOI: 10.1192/bjp.180.5.396CrossRefGoogle ScholarPubMed
Brunello, N, Mendlewicz, J, Kasper, Set al. The role of noradrenaline and selective noradrenaline reuptake inhibition in depression. Eur Neuropsychopharmacol 2002;12: 461–475.CrossRefGoogle ScholarPubMed
Niklson, IA, Reimitz, PE, Sennef, C. Factors that influence the outcome of placebo-controlled antidepressant clinical trials. Psychopharmacol Bull 1997;33: 41–51.Google ScholarPubMed
Katz, MM, Halbreich, UM, Bowden, CLet al. Enhancing the technology of clinical trials and the trials model to evaluate newly developed, targeted antidepressants. Neuropsychopharmacology 2002;27: 319–328.DOI: 10.1016/S0893-133X(02)00329-9CrossRefGoogle ScholarPubMed
Montgomery, SA, Bech, P, Blier, Pet al. Selecting methodologies for the evaluation of differences in time to response between antidepressants. J Clin Psychiatry 2002;63: 694–699.CrossRefGoogle ScholarPubMed
Pinder, RM. Designing a new generation of antidepressant drugs. Acta Psychiatr Scand 1997;96(Suppl. 391): 7–13.CrossRefGoogle Scholar
Pinder, RM. On the feasibility of designing new antidepressants. Hum Psychopharmacol 2001;16: 53–59.DOI: 10.1002/hup.183CrossRefGoogle ScholarPubMed
Andrews, JS, Pinder, RM. Chemistry and pharmacology of novel antidepressants. In: Leonard, BE, ed. Antidepressants. Basel: Birkhäuser, 2001: 123–145. CrossRefGoogle Scholar
Nutt, DJ, Pinder, RM. α2-Adrenoceptors and depression. J Psychopharmacol 1996;10(Suppl. 3):35–42. Google Scholar
De Boer, TH, Nefkens, F, Van Helvoirt, A, Van Delft, AML. Differences in modulation of noradrenergic and serotonergic transmission by the alpha-2 adrenoceptor antagonists, mirtazapine, mianserin and idazoxan. J Pharmacol Exp Ther 1996;277: 852–860.Google ScholarPubMed
Montgomery, SA. Is there a role for a pure noradrenergic drug in the treatment of depression? Eur Neuropsychopharmacol 1997;7(Suppl. 1):S3–S9.DOI: 10.1016/S0924-977X(97)00414-8CrossRefGoogle Scholar
Skolnick, P. Antidepressants: new pharmacological strategies. Totowa, NJ: Humana Press, 1997. CrossRefGoogle Scholar
Leonard, BE. Noradrenaline in basic models of depression. Eur Neuropsychopharmacol 1997;7(Suppl. 1):S11–S16.DOI: 10.1016/S0924-977X(97)00415-XCrossRefGoogle ScholarPubMed
Delgado, PL, Moreno, FA, Potter, R, Gelenberg, AJ. Norepinephrine and serotonin in antidepressant action: evidence from neurotransmitter depletion studies. In: Briley, M, ed. Antidepressant therapy at the dawn of the third millennium. London: Martin Dunitz, 1997: 140–161. Google Scholar
Delgado, PL, Moreno, FA, Onate, L, Gelenberg, AJ. Sequential catecholamine and serotonin depletion in mirtazapine-treated depressed patients. Int J Neuropsychopharmacol 2002;5: 63–66.DOI: 10.1017/S1461145702002778CrossRefGoogle ScholarPubMed
Mongeau, R, Blier, P, De Montigny, C. The serotonergic and noradrenergic systems of the hippocampus: their interactions and the effects of antidepressant treatments. Brain Res Rev 1997;23: 145–195.DOI: 10.1016/S0165-0173(96)00017-3CrossRefGoogle ScholarPubMed
Millan, MJ, Lejeune, F, Gobert, A. Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents. J Psychopharmacol 2000;14: 114–138.CrossRefGoogle Scholar
Szabo, ST, Blier, P. Effects of the selective norepinephrine reuptake inhibitor reboxetine on norepinephrine and serotonin transmission in the rat hippocampus. Neuropsychopharmacology 2001;25: 845–857.DOI: 10.1016/S0893-133X(01)00284-6CrossRefGoogle ScholarPubMed
Potter, WZ, Schmidt, ME. Noradrenergic and other new antidepressants. In: Halbreich, U, Montgomery, SA, eds. Pharmacotherapy for mood, anxiety and cognitive disorders. Washington, DC: American Psychiatric Press, 2000: 237–253. Google Scholar
Amara, SG, Kuhar, MJ. Neurotransmitter transporters: Recent progress. Annu Rev Neurosci 1993;16: 73–93.DOI: 10.1146/annurev.ne.16.030193.000445CrossRefGoogle ScholarPubMed
Porzgen, P, Bonisch, H, Bruss, M. Molecular cloning and organization of the coding region of the human norepinephrine transporter gene. Biochem Biophys Res Commun 1995;215: 1145–1150.DOI: 10.1006/bbrc.1995.2582CrossRefGoogle ScholarPubMed
Zill, P, Engel, R, Baghai, Tet al. Identification of a naturally occurring polymorphism in the promoter region of the norepinephrine transporter and analysis in major depression. Neuropsychopharmacology 2002;26: 489–493.DOI: 10.1016/S0893-133X(01)00386-4CrossRefGoogle ScholarPubMed
Giros, B, Wang, YM, Suter, S, McLeskey, SB, Piff, C, Caron, MG. Delineation of discrete domains for substrate, cocaine, and tricyclic antidepressant interactions using chimeric dopamine–norepinephrine transporters. J Biol Chem 1994;269: 15985–15988.CrossRefGoogle ScholarPubMed
Madras, BK, Pristupa, ZB, Niznik, HBet al. Nitrogen-based drugs are not essential for blockade of monoamine transporters. Synapse 1996;24: 340–348.DOI: 10.1002/(SICI)1098-2396(199612)24:4<340::AID-SYN4>3.3.CO;2-J3.0.CO;2-D>CrossRefGoogle Scholar
Bylund, DB, Eikenberg, DC, Hieble, JPet al. International union of pharmacology nomenclature of adrenoceptors. Pharmacol Rev 1994;46: 121–136.Google ScholarPubMed